

Orhan Aktas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3363252/publications.pdf>

Version: 2024-02-01

219
papers

16,320
citations

17440

63
h-index

18130

120
g-index

223
all docs

223
docs citations

223
times ranked

14788
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
2	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	2.0	16
3	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	4
4	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism. <i>Redox Biology</i> , 2022, 49, 102221.	9.0	6
5	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.1	14
6	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	7.2	82
7	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. <i>Brain Stimulation</i> , 2022, 15, 403-413.	1.6	6
8	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	64
9	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 978-985.	1.9	17
10	Thinking outside the box: non-canonical targets in multiple sclerosis. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 578-600.	46.4	31
11	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
12	Worldwide Incidence and Prevalence of Neuromyelitis Optica. <i>Neurology</i> , 2021, 96, 59-77.	1.1	101
13	Anti-CD20 therapies and pregnancy in neuroimmunologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	43
14	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 15-28.	3.7	11
15	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	3.3	11
16	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
17	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	16
18	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20

#	ARTICLE	IF	CITATIONS
19	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.3	72
20	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
21	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	41
22	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
23	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	12
24	Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue. <i>Frontiers in Neurology</i> , 2021, 12, 696807.	2.4	1
25	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	65
26	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	47
27	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
28	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. <i>Journal of Neuroimmunology</i> , 2021, 360, 577699.	2.3	16
29	Targeting B Cells to Modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	37
30	Targeting B cells to modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	30
31	Relapse-independent multiple sclerosis progression under natalizumab. <i>Brain Communications</i> , 2021, 3, fcb229.	3.3	14
32	Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal. <i>Frontiers in Neurology</i> , 2021, 12, 785180.	2.4	3
33	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. <i>Lancet Neurology</i> , The, 2021, 20, 991-1000.	10.2	16
34	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	4.8	4
35	Serum neurofilament light chain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	25
36	Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106142.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials. <i>BMC Neuroscience</i> , 2020, 21, 48.	1.9	0
38	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	7.2	84
39	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	7.2	44
40	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. <i>BMC Neurology</i> , 2020, 20, 333.	1.8	2
41	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 782.	2.4	6
42	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
43	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal and Temporal Sector in a Case Series. <i>Frontiers in Neurology</i> , 2020, 11, 508.	2.4	3
44	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2020, 19, 280-281.	10.2	10
45	Altered fovea in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	50
46	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. <i>Microcirculation</i> , 2020, 27, e12616.	1.8	1
47	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
48	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	4.1	1
49	Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report. <i>BMC Neurology</i> , 2020, 20, 158.	1.8	18
50	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29
51	COVID-19 and management of neuroimmunological disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 347-348.	10.1	32
52	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
53	Author response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 95, 610-610.	1.1	0
54	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. <i>BMC Neurology</i> , 2019, 19, 190.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019, 33, 659-676.	5.9	12
56	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. <i>Frontiers in Neurology</i> , 2019, 10, 741.	2.4	3
57	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 290-295.	2.1	6
58	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019, 16, 203.	7.2	28
59	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	13.7	433
60	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	1.0	34
61	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. <i>Annals of Neurology</i> , 2019, 85, 615-617.	5.3	3
62	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. <i>Journal of Neurology</i> , 2019, 266, 1421-1428.	3.6	29
63	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. <i>Neuroscience Letters</i> , 2019, 704, 116-125.	2.1	21
64	Misdiagnoses and delay of diagnoses in Moyamoya angiopathyâ€”a large Caucasian case series. <i>Journal of Neurology</i> , 2019, 266, 1153-1159.	3.6	28
65	Meningitis gone viral: description of the echovirus wave 2013 in Germany. <i>BMC Infectious Diseases</i> , 2019, 19, 1010.	2.9	8
66	Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. <i>Current Opinion in Neurology</i> , 2019, 32, 346-357.	3.6	8
67	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 â€” continuity and change. <i>Current Opinion in Neurology</i> , 2019, 32, 327-337.	3.6	32
68	Monoclonal Antibodies for Multiple Sclerosis: An Update. <i>BioDrugs</i> , 2019, 33, 61-78.	4.6	21
69	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019, 42, 633-647.	3.2	18
70	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	2.3	22
71	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 92, e48-e54.	1.1	95
72	Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 93, 767-768.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2018, 146, 86-98.	3.9	26
74	Interferon \hat{I}^2 -1a and \hat{I}^2 -1b for patients with multiple sclerosis: updates to current knowledge. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 137-153.	3.0	36
75	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. <i>Journal of Neuroinflammation</i> , 2018, 15, 71.	7.2	37
76	Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination. <i>Multiple Sclerosis Journal</i> , 2018, 24, 550-551.	3.0	3
77	Long-term adherence and subjective treatment effect of botulinum toxin in different neurologic diseases. <i>Toxicon</i> , 2018, 156, S67-S68.	1.6	0
78	Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 952-961.	3.7	7
79	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , 2018, 32, 1159-1171.	5.9	38
80	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.1	140
81	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
82	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1776-1778.	3.0	18
83	Predictors of response to opicinumab in acute optic neuritis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1154-1162.	3.7	19
84	Neue, experimentelle und zukünftige Therapieansätze. , 2018, , 353-359.		0
85	Alterations of the outer retina in non-arteritic anterior ischaemic optic neuropathy detected using spectral-domain optical coherence tomography. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 496-508.	2.6	7
86	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 189-199.	10.2	210
87	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
88	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017, 65, 1521-1534.	4.9	33
89	Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 661-665.	1.6	13
90	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812.	10.2	397

#	ARTICLE	IF	CITATIONS
91	Fulminant intramedullary spinal cord sarcoidosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 47-48.	2.0	2
92	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017, 264, 1370-1380.	3.6	55
93	Functional reorganization is a maladaptive response to injury â€œ NO. <i>Multiple Sclerosis Journal</i> , 2017, 23, 193-194.	3.0	15
94	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e363.	6.0	37
95	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
96	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 909-914.	3.7	11
97	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2016, 1, e000008.	1.6	9
98	Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 63.	3.7	6
99	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 199-204.	3.6	40
100	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialâ€”study protocol. <i>BMJ Open</i> , 2016, 6, e010956.	1.9	46
101	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228
102	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	1.8	13
103	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. <i>Molecular Neurodegeneration</i> , 2016, 11, 53.	10.8	13
104	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	7.2	351
105	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.2	686
106	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.2	217
107	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	1.9	184
108	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.2	202

#	ARTICLE	IF	CITATIONS
109	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	7.2	23
110	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
111	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
112	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016, 13, 47-57.	4.4	38
113	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	10.2	266
114	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	3.6	53
115	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	6.0	53
116	BAX inhibitor-1 is a Ca ²⁺ channel critically important for immune cell function and survival. <i>Cell Death and Differentiation</i> , 2016, 23, 358-368.	11.2	29
117	Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 43-55.	3.7	71
118	Redox-regulated fate of neural stem progenitor cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1543-1554.	2.4	37
119	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 756.	9.0	206
120	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
121	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 406-408.	2.0	10
122	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. <i>Journal of Neurology</i> , 2015, 262, 1379-1384.	3.6	47
123	Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. <i>BMC Infectious Diseases</i> , 2015, 15, 61.	2.9	29
124	IFN γ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 20.	5.2	89
125	Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. <i>Clinical Neurophysiology</i> , 2015, 126, 2040-2041.	1.5	14
126	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	3.2	34

#	ARTICLE	IF	CITATIONS
127	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015, 85, 521-527.	1.1	24
128	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015, 85, 610-618.	1.1	50
129	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104
130	Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 243-243.	1.9	9
131	Alemtuzumab: A new therapy for active relapsing/remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 22-34.	3.0	92
132	Premature aging of the hippocampal neurogenic niche in adult Bmal1-deficient mice. <i>Aging</i> , 2015, 7, 435-449.	3.1	48
133	Neue, experimentelle und zukünftige Therapieansätze. , 2015, , 361-368.		0
134	Subtle retinal pathology in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 290-297.	3.7	57
135	Photoreceptor layer thinning in Parkinsonian syndromes. <i>Movement Disorders</i> , 2014, 29, 1222-1223.	3.9	13
136	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. <i>Journal of Neuroinflammation</i> , 2014, 11, 129.	7.2	24
137	Interferon- γ -related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. <i>BMC Neurology</i> , 2014, 14, 247.	1.8	21
138	Natalizumab in clinical practice: managing the risks, enjoying the benefits. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1181-1181.	1.9	4
139	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014, 11, 46.	7.2	100
140	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
141	Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. <i>Neurogenetics</i> , 2014, 15, 129-134.	1.4	19
142	Immune regulation of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2014, 122, 3-14.	1.8	28
143	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 617-620.	3.0	47
144	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013, 136, 1778-1782.	7.6	60

#	ARTICLE	IF	CITATIONS
145	Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 390.	9.0	112
146	Immunoproteasomes Are Important for Proteostasis in Immune Responses. <i>Cell</i> , 2013, 152, 935-937.	28.9	39
147	Characteristics of Susac syndrome: a review of all reported cases. <i>Nature Reviews Neurology</i> , 2013, 9, 307-316.	10.1	293
148	Genome-wide significant association of ANKRD55rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013, 50, 140-143.	3.2	34
149	Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20057-20062.	7.1	77
150	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1887-1895.	3.0	141
151	Ein Paradigmenwechsel und die Zukunft. , 2013, , 189-196.		0
152	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , 2012, 79, 285-287.	1.1	47
153	Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6650-6655.	7.1	193
154	Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1422-1429.	3.0	108
155	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 239.	4.5	276
156	Is It Too Early to Predict the Failure of Natalizumab in NMO?â€”Reply. <i>Archives of Neurology</i> , 2012, 69, 1085.	4.5	4
157	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.8	111
158	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29â€¦000 subjects: Figure 1. <i>Journal of Medical Genetics</i> , 2012, 49, 558-562.	3.2	31
159	p57kip2 regulates glial fate decision in adult neural stem cells. <i>Development (Cambridge)</i> , 2012, 139, 3306-3315.	2.5	27
160	Optical Coherence Tomography in Parkinsonian Syndromes. <i>PLoS ONE</i> , 2012, 7, e34891.	2.5	145
161	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.2	593
162	Independent replication of STAT3 association with multiple sclerosis risk in a large German caseâ€“control sample. <i>Neurogenetics</i> , 2012, 13, 83-86.	1.4	21

#	ARTICLE	IF	CITATIONS
163	Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. <i>Clinical Immunology</i> , 2012, 142, 15-24.	3.2	88
164	Cladribine as a therapeutic option in multiple sclerosis. <i>Clinical Immunology</i> , 2012, 142, 68-75.	3.2	13
165	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. <i>PLoS ONE</i> , 2012, 7, e38741.	2.5	52
166	Retinal Neurodegeneration in Wilson's Disease Revealed by Spectral Domain Optical Coherence Tomography. <i>PLoS ONE</i> , 2012, 7, e49825.	2.5	43
167	Electrostatically stabilized magnetic nanoparticles – an optimized protocol to label murine T cells for in vivo MRI. <i>Frontiers in Neurology</i> , 2011, 2, 72.	2.4	12
168	Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. <i>Lancet Neurology</i> , The, 2011, 10, 293-295.	10.2	27
169	Beyond axonal transection: Hippocampal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 69, 433-436.	5.3	2
170	The complex world of oligodendroglial differentiation inhibitors. <i>Annals of Neurology</i> , 2011, 69, 602-618.	5.3	119
171	Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. <i>Glia</i> , 2011, 59, 132-142.	4.9	51
172	Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation. <i>PLoS ONE</i> , 2011, 6, e25456.	2.5	75
173	Development of oral cladribine for the treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2010, 257, 163-170.	3.6	40
174	Oral therapies for multiple sclerosis: are we there yet?. <i>Lancet Neurology</i> , The, 2010, 9, 454-457.	10.2	7
175	Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress. <i>Cell</i> , 2010, 142, 613-624.	28.9	482
176	Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. <i>Trends in Neurosciences</i> , 2010, 33, 140-152.	8.6	89
177	Fingolimod is a potential novel therapy for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 373-382.	10.1	165
178	Cytotoxic CD8 ⁺ T Cell-Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. <i>Journal of Neuroscience</i> , 2009, 29, 15397-15409.	3.6	78
179	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2009, 66, 310-322.	5.3	151
180	Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope. <i>Annals of Neurology</i> , 2009, 66, 429-432.	5.3	23

#	ARTICLE	IF	CITATIONS
181	Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. <i>Journal of Neurology</i> , 2009, 256, 1906-1908.	3.6	6
182	Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. <i>Nature Medicine</i> , 2009, 15, 788-793.	30.7	118
183	Beyond blood brain barrier breakdown – in vivo detection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI. <i>Journal of Neuroinflammation</i> , 2009, 6, 20.	7.2	41
184	Sirt1 contributes critically to the redox-dependent fate of neural progenitors. <i>Nature Cell Biology</i> , 2008, 10, 385-394.	10.3	412
185	Autoregulation of Th1-mediated inflammation by <i>twist1</i> . <i>Journal of Experimental Medicine</i> , 2008, 205, 1889-1901.	8.5	96
186	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e1928.	2.5	110
187	Neuronal Damage in Brain Inflammation. <i>Archives of Neurology</i> , 2007, 64, 185.	4.5	193
188	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007, 16, 479-484.	2.0	20
189	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 342-349.	8.7	56
190	The role of TRAIL/TRAIL receptors in central nervous system pathology. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 2912.	3.0	61
191	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. <i>Journal of Neuroimmunology</i> , 2007, 184, 17-26.	2.3	42
192	Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. <i>Experimental Brain Research</i> , 2007, 178, 542-553.	1.5	23
193	Revised diagnostic criteria for neuromyelitis optica – incorporation of NMO-IgG status. <i>Nature Clinical Practice Neurology</i> , 2007, 3, E1-E1.	2.5	15
194	TRAIL limits excessive host immune responses in bacterial meningitis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2004-2013.	8.2	62
195	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. <i>PLoS Medicine</i> , 2007, 4, e133.	8.4	187
196	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. <i>Trends in Neurosciences</i> , 2006, 29, 518-527.	8.6	329
197	Death Ligands and Autoimmune Demyelination. <i>Neuroscientist</i> , 2006, 12, 305-316.	3.5	38
198	Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1. <i>Journal of Immunology</i> , 2005, 174, 5630-5635.	0.8	59

#	ARTICLE	IF	CITATIONS
199	New aspects regarding mechanisms of tissue damage in the course of autoimmune demyelination. Signal Transduction, 2005, 5, 245-249.	0.4	0
200	Frequency of blood CX3CR1 ⁺ positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB Journal, 2005, 19, 1902-1904.	0.5	85
201	Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB Journal, 2005, 19, 1347-1349.	0.5	261
202	Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL. Neuron, 2005, 46, 421-432.	8.1	211
203	Multiple Sklerose – weit mehr als eine Entmarkungskrankheit. E-Neuroforum, 2004, 10, 188-194.	0.1	0
204	Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Multiple Sclerosis Journal, 2004, 10, 182-187.	3.0	48
205	Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue. Journal of Neuroscience, 2004, 24, 2458-2464.	3.6	134
206	Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain, 2004, 127, 111-119.	7.6	194
207	Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF- κ B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis. Journal of Immunology, 2004, 173, 5794-5800.	0.8	314
208	Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. Journal of Neuroimmunology, 2004, 149, 195-201.	2.3	25
209	Systemic IFN- γ treatment induces apoptosis of peripheral immune cells in MS patients. Journal of Neuroimmunology, 2003, 137, 187-196.	2.3	44
210	TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet, The, 2003, 361, 2036-2043.	13.7	194
211	Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin. Journal of Experimental Medicine, 2003, 197, 725-733.	8.5	271
212	Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation. Journal of Experimental Medicine, 2003, 198, 1729-1740.	8.5	137
213	Induction of Apoptosis of CD4 ⁺ T Cells by Immunomodulatory Therapy of Multiple Sclerosis with Glatiramer Acetate. European Neurology, 2003, 50, 200-206.	1.4	24
214	Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy. Current Pharmaceutical Design, 2003, 9, 245-256.	1.9	23
215	Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain. Journal of Neuroscience, 2002, 22, RC209-RC209.	3.6	106
216	Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 213-220.	2.3	31

#	ARTICLE	IF	CITATIONS
217	Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. <i>Journal of Neuroimmunology</i> , 2001, 114, 160-167.	2.3	41
218	Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells â€” implications for multiple sclerosis1This work was supported by grants from the DFG, the Hertie-Stiftung and the DMSG.1. <i>Journal of Neuroimmunology</i> , 2000, 103, 69-75.	2.3	4
219	Therapie der multiplen Sklerose: MedikamentÃ¶se AnsÃ¤tze zur Remyelinisierung in PrÃ¼fung. , 0, , .		0